Objective: We retrospectively elucidated the oncological outcomes, prognostic factors and toxicities of proton beam therapy in trimodal bladder-preserving therapy for muscle-invasive bladder cancer at our institution. Methods: From 1990 to 2015, 70 patients with cT2-3N0M0 muscle-invasive bladder cancer underwent trimodal bladder-preserving therapy consisting of maximal transurethral resection of the bladder tumor, small pelvis photon irradiation, intra-arterial chemotherapy and proton beam therapy. The overall survival rate, progression-free survival rate, time to progression, predictive factors for progression and toxicities were analyzed. Progression was defined as when muscleinvasive recurrence, distant metastasis or upper urinary tract recurrence was observed. Results: The patients' median age was 65 (range 36-85) years. The median follow-up period was 3.4 (range 0.6-19.5) years. The 5-year cumulative overall survival rate, progression-free survival rate and time to progression rate were 82%, 77%, and 82%, respectively. In univariate and multivariate analyses, tumor multiplicity and tumor size (≥5 cm) were significant and independent factors associated with progression (hazard ratio 3.5, 95% confidence interval 1.1-12; hazard ratio 5.0, 95% confidence interval 1.3-17; P < 0.05 for all). As for toxicity, 26 (18%) patients had grade 3-4 acute hematologic toxicities and 2 (3%) patients had grade 3 late genitourinary toxicity. No patient had to discontinue the treatment due to acute toxicity. Conclusions: Our bladder-preserving therapy with proton beam therapy was well tolerated and achieved a favorable mortality rate. Tumor multiplicity and tumor size were important risk factors for progression. Our findings indicate that this therapy can be an effective treatment option for selected muscle-invasive bladder cancer patients.
Introduction
Radical cystectomy (RC) with urinary diversion is a standard treatment for muscle-invasive bladder cancer (MIBC) (1, 2) , with a reported 5-year survival rate of 40-60% (3) . Although the complications and mortality rate of this treatment have decreased due to advances in surgical techniques and perioperative patient care, RC with urinary diversion has a strong potential to decrease patients' post-treatment comfort and quality of life (QOL) (3) (4) (5) . To improve patients' QOL without compromising their oncological outcomes, bladder-preserving therapy with curative intent using a trimodal treatment consisting of transurethral resection of the bladder tumor (TURBT), chemotherapy and radiation therapy (RT) was developed beginning in the early 1980s (6, 7) . Since then, several groups have modified their own protocols of bladder-preserving therapies and reported the following outcomes: the tumor control rate has ranged from 70-90%, the overall survival (OS) rate has been 50-75% and the 5-year cancer-specific survival rate has been 50-80% (8) (9) (10) .
Proton beams can achieve excellent dose localization to the target compared with photon beams (11) , and thus proton beam therapy (PBT) can deliver a large irradiation dose to a tumor site while sparing the surrounding normal tissues such as the small/large intestine and normal bladder wall. To focus on this advantage, our institute has performed original bladder-preserving therapy including PBT since 1990, and we reported favorable oncological outcomes in initial studies that included the patients who underwent this therapy until 2006 (12, 13) . As of 2016, we have continued to use this treatment protocol, and more than 70 patients have undergone this bladder-preserving therapy including PBT. Here, we describe the oncological outcomes and prognostic factors identified by our analysis of the 70 patients' cases and provide detailed information about the acute and late toxicities of bladder-preserving therapy including PBT that we have observed to date.
Patients and methods

Patient eligibility
We conducted a retrospective analysis of 70 consecutively treated patients diagnosed with clinical T2-3N0M0 MIBC who were treated with bladder-preserving therapy including PBT at the University of Tsukuba, Japan, from January 1990 to December 2015. This study was approved by the University's Institutional Review Board (No. 634). Patients who had pathologically confirmed primary MIBC with tumor stage T2-3N0M0 according to the International Union Against Cancer (UICC) 2009 TNM classification based on evaluations by computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, chest X-ray and bone scintigraphy were eligible for our bladder-preserving therapy. Patients who had a poor general condition (World Health Organization performance status of 3 or poorer) or who had a history of systemic chemotherapy or pelvic irradiation were ineligible for our bladder-preserving therapy. Patients who had a short follow-up period (<6 months) were excluded from this analysis. Written informed consent was obtained from all patients before the bladder-preserving therapy.
Induction therapy
The treatment protocol for our bladder-preserving therapy is described in detail elsewhere (13) , but a schema of the protocol is shown in Fig. 1 . Briefly, TURBT and bladder-mapping biopsies were initially performed to confirm the histopathological diagnosis (including the extent of tumor invasion into the bladder wall) and to reduce tumor volume. After the TURBT, intra-arterial chemotherapy combined with external-beam RT was administered as induction therapy.
Until 2008, we performed small pelvis RT with 10-MV photon beams using anteroposterior (AP)-posteroanterior (PA) opposed fields, but in 2008 we switched to the four-field technique using opposing lateral fields in addition to AP-PA fields along with three-dimensional treatment planning, with Xio software (Elekta, Stockholm, Sweden). The clinical target volume (CTV) included all areas of gross and potentially microscopic disease consisting of the tumor, the bladder and pelvic lymph nodes (internal iliac, external iliac, obturator and presacral lymph nodes). The planning target volume included the CTV plus a 5-mm margin for positioning uncertainty, and the positions of the multi-leaf collimators were set to cover the CTV by at least 95% of the prescribed dose. A total dose of 41.4 Gy in 23 fractions was delivered with a daily fractional dose of 1.8 Gy, 5 fractions per week (Fig. 1) .
Concurrently, intra-arterial chemotherapy was administered. The catheters were inserted into the bilateral internal iliac arteries by the Seldinger method, and embolization of the bilateral superior gluteal arteries with coils was performed to concentrate the chemotherapeutic agents on the tumor site and avoid their flow to other organs. Subsequently, methotrexate 30 mg/m 2 and cisplatin 50 mg/m 2 were administered half-and-half continuously over a 2-hour period each in three courses in weeks 1, 4 and 7 through the catheters placed in the bilateral internal iliac arteries. The catheters were removed immediately after the administration of the agents at each course.
Tumor re-evaluation
Three to four weeks after the completion of the induction therapy, we also evaluated the treatment response of the initial therapy, as described (13) . A tumor re-evaluation was conducted that included a biopsy of the primary tumor site, urine cytology and diagnostic imaging using CT and MRI. In patients without residual tumor, PBT was performed only for the primary tumor site.
To visualize the location of the tumor bed and to confirm the positioning for each treatment, four to five fiducial markers were implanted around the primary tumor site using cystoscopy before the treatment planning for PBT. The incomplete responders displaying residual tumor generally underwent an RC.
From January 1990 to December 2015, 135 patients were enrolled in the induction therapy. After the tumor re-evaluation, 115 (85.1%) patients achieved a complete response (CR). Among the 115 patients with a CR to induction therapy, 70 patients underwent PBT. The cases of these 70 patients were evaluated in this study. Based on the patients' decision, the other patients did not undergo PBT: 27 patients underwent photon irradiation boost therapy, 1 underwent a cystectomy and 5 declined any further therapy after the induction therapy. All of these patients were excluded from the analysis in this study.
Proton beam therapy
CT images at 5-mm intervals at the spine position were acquired for the PBT treatment planning, and the CTV was created as the primary tumor bed (with reference to the positions of the fiducial markers) plus a 5-mm margin. The bolus and smear margins were set to cover the CTV by a 95% prescribed dose using Hitachi software. A fractional dose of 3.3 Gy equivalent (GyE) was used, and a total dose of 36.3 GyE in 11 fractions was given over a 2-week period. Thus, the total dose of the small pelvic RT with photons plus the local PBT boost was 77.7 Gy in 34 fractions. This is equivalent to~80.9 Gy by doses of 2 Gy per fraction equivalent using a linear quadratic model when the alpha/beta ratio is 10 for bladder cancer. Figure 2 shows the 95%, 70%, 50% and 10% isodose lines of the PBT.
Follow-up procedures and criteria for toxicity
All patients routinely underwent cystoscopy, urine cytology and chest X-ray every 3 months for the first year after the therapy, and every 6 months for 5 years thereafter. Chest to pelvic CT was also performed every 6 months. We evaluated acute and late toxicities associated with treatment according to according to the US National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4 (14).
Outcomes and statistics
Progression was defined as when muscle-invasive recurrence, distant metastasis or upper urinary tract recurrence was observed. OS was defined as the interval from the date of the beginning of induction therapy to the date of death by any cause. Progression-free survival (PFS) was defined as the interval from the date of the beginning of induction therapy to the date of progression or death by any cause.
Time to progression (TTP) was defined as the interval from the date of the beginning of induction therapy to the date of progression. The cases of the patients who were alive without progression and who had died from causes unrelated to bladder cancer were censored at the date of the last available follow-up day. We estimated the OS rate, PFS rate, and TTP rate of all patients by the KaplanMeier method. To detect prognostic factors for progression, we performed univariate and multivariate analyses based on the TTP. The univariate analysis was performed by log-rank test. Multivariate analyses were performed using a stepwise reduced model and a Cox proportional hazard regression model. That is, we applied the factors that were statistically significant for progression in the univariate analysis and other clinical values -e.g. hydronephrosis (8, 9) and concomitant carcinoma in situ (CIS) (15) , which are historically thought to be clinically important factors in bladder-preserving therapy -to the stepwise reduced model, and we determined the valuables that were put in the Cox proportional hazard regression model. All statistical comparisons were two-sided, and P values <0.05 were considered significant. JMP software (version 9; SAS Institute, Cary, NC) was used.
Results
Patient characteristics
We retrospectively analyzed the cases of 70 consecutive patients with clinical T2-3N0M0 MIBC who underwent our bladderpreserving therapy at our institution. The median age of these patients was 65 years (range 36-85), and the median follow-up period was 3.4 years (range 0.6-19.5).
The patients' pretreatment characteristics are summarized in Table 1 . The clinical T stage was T2 in 51 patients (73%) and T3 in 19 patients (27%), and 9 of the patients (13%) had concomitant CIS. Fifty patients (71%) had a solitary tumor, 61 (87%) had a primary tumor <5 cm, 7 (10%) had a tumor located at the bladder neck and 7 (10%) had hydronephrosis.
OS, PFS and TTP
The 3-, 5-and 10-year cumulative OS rates of all 70 patients were 90%, 82% and 78% (Fig. 3A) , respectively. The 3-, 5-and 10-year PFS rates were 80%, 77% and 73% (Fig. 3B) , respectively. The 3-, 5-and 10-year TTP rates were 82%, 82% and 82% (Fig. 3C) , respectively. During the follow-up period, three patients underwent an RC with urinary diversion (ilial conduit: two patients; ureterostomy: one patient). The reasons for RC were MIBC recurrence (two patients) and uncontrollable NMIBC (one patient). The operations were safely performed, and there was no severe perioperative complication. Twelve patients (17%) had progression; four patients had MIBC recurrence, four patients had visceral metastases (three in the lung, one in the peritoneum) and four patients had pelvic lymph node metastases. Eleven of the 12 patients showed the progression within 3 years after the treatment, and 7 eventually died of the disease.
Prognostic factors for progression
As shown in Table 2 , in the univariate analysis, multiplicity (i.e. multiple tumors at initial diagnosis) and tumor size ≥5 cm were associated with progression (P = 0.025 and 0.0054, respectively) ( Fig. 3D-1,2 ), but cT2 versus cT3 stage was not related to progression in our series. In the multivariate analyses, multiplicity [P = 0.032, hazard ratio (HR) 3.5, 95% confidence interval (CI) 1.1-12] and tumor size (P = 0.022, HR 5.0, 95% CI 1.3-17) were identified as independent prognostic factors for progression (Table 2 ). These results indicated that the patients who had multiple tumors or a primary tumor ≥5 cm in size were at risk of progression and were thus not suitable for our trimodal therapy.
Toxicity
The therapy-related acute and late toxicities are summarized in Table 3 . Grade 3 or higher hematologic toxicities were observed in 18 (26%) patients: 15 (21%) patients had a grade 3 white blood cell count decrease, and 1 patient (1%) each had febrile neutropenia, grade 3 anemia and a grade 3 platelet count decrease. Regarding non-hematological toxicities, a grade 4 thromboembolic event was observed in one patient, but the symptom was resolved successfully. No individual had to discontinue the treatment due to acute hematological or non-hematological toxicities.
Concerning late toxicity, one patient had a grade 2 rectal hemorrhage, three patients (4%) had a grade 2 urinary tract hemorrhage and two patients (3%) had a grade 3 urinary tract obstruction, but these toxicities were resolved by conservative treatments.
Discussion
Although various types of bladder-preserving therapies have been reported, it is generally accepted that a trimodal therapy approach leads to acceptable outcomes. Generally in this approach, induction therapy including maximal transurethral resection (TUR), RT at 40-45 Gy and several courses of concurrent intravenous chemotherapy are performed, and patients who achieve a CR to induction therapy receive an irradiation boost with 20-25 Gy doses to the primary tumor sites (10) . Patients who do not achieve a CR immediately undergo an RC because of the priority of survival benefit.
The main characteristic feature of our treatment protocol is the use of PBT instead of photons in the irradiation boost. We use PBT because protons have unique physical characteristics and can deliver high irradiation doses to the local tumor site without severe toxicity (16, 17) . Unlike our reports in 2006, the present study population was large enough, and our present analysis revealed the following three important results.
The first is that our treatment regimen achieves a high local control rate. Only four (6%) patients had MIBC recurrence, and this result is lower than the recurrence rates of previous protocols (ranging from 11% to 43%), which is probably due to the higher irradiation dose (77.7 Gy) given by PBT than the 65-70 Gy dose in other studies (10) . Dose escalation to control a local tumor is a reasonable approach, but it may cause severe morbidities in at-risk organs such as the small intestine and the rectum around the bladder (18) . In our treatment, PBT contributed to the high local control rate because it delivered high-dose irradiation without any severe toxicity.
The second important finding of the present study is the identification of valid prognostic factors for progression in bladderpreserving therapy for MIBC. Twelve (17%) patients showed progression during the follow-up period. Seven of these patients had multiple tumors at the initial diagnosis, and four had a large (≥5 cm) primary tumor. These two factors were identified in the univariate analysis as significant factors for progression, and they were revealed to be independent significant factors for progression in the multivariate analyses.
The impact of several pretreatment variables on oncologic outcomes was assessed in previous studies. Hydronephrosis (8, 9) , incomplete TUR before the therapy (8, 9) and tumor multiplicity (15, 19, 20) have been suggested to be poor prognostic factors for bladder-preserving therapy. In the present study, hydronephrosis was not a significant factor for progression, probably due to the selection criteria used, which were poor oncological outcomes or risks of permanent ureteral stenosis after the therapy. Tumor multiplicity was confirmed to be a significant factor for progression, as in previous studies (15, 19, 20) .
Regarding tumor size, Bellmunt et al. noted that <5 cm primary tumor is described as a good indication for bladder-preserving therapy in the guidelines of the European Society of Medical Oncology (ESMO) (21) , but the evidence of 5 cm has not been clear (22) . In the present study, tumor size ≥5 cm was also a significant prognostic factor for progression. Tumor size <5 cm can thus be regarded as a good indication for bladder-preserving therapy, as mentioned by the ESMO.
Many molecular biological markers for the pathogenesis of bladder cancer have also been investigated (23) , and some groups have attempted to apply these markers for clinical use in bladderpreserving therapy. Onozawa et al. reported that the labeling index of Ki-67, a cell proliferation marker, was useful for evaluating the biological characters of primary MIBC and recurrent NMIBC after bladder-preserving therapy (20) . Inoue et al. reported that the level of ERBB2 (a cell proliferation, differentiation and invasion marker) in primary MIBC was a prognostic factor for bladder cancer mortality (24) . Those molecular markers may be helpful in determining whether patients are ideal candidates for bladder-preserving therapy, but further studies are needed to confirm this. The last important point of the present study was that the toxicity following our trimodal therapy was in the allowable range despite the use of a high irradiation dose. In a recent review of bladder-preserving therapy studies, the rates of hematologic, Gastrointestinal (GI) and Genitourinary (GU) grade 3-4 acute toxicities ranged from 10% to 36% (10) and the treatment completion rates were 80-90% (10). In our regimen, grade 3-4 hematologic toxicities occurred in 26% of the patients, but no grade 3-4 GI or GU acute toxicities were observed. Consequently, all patients have completed their treatments as scheduled.
Intra-arterial chemotherapy in induction therapy may contribute to a low incidence of acute toxicity, but there are few reports about bladder-preserving therapy that included intra-arterial chemotherapy (25) and there is as yet no evidence to support this idea.
Concerning late toxicity, in a recent review, low-grade (grade 1-2) toxicity rates ranged from 5% to 6% for GI toxicities and from 10% to 25% for GU toxicities (8, 10) . Late grade 3 GU toxicity rates ranged from 3% to 8% (10, 19, 26) . In our present patient series, the low-grade toxicity rates were 1% for GI and 4% for GU, and the grade 3 late GU toxicity rate was 3%. Our late GI and GU toxicity results are better than those of the previous studies. The use of PBT might have contributed to this improvement.
The potential limitations of our study should be considered. First, our results reflect a retrospective experience. Second, PBT might be difficult to adopt in community settings. Third, we did not directly evaluate the patients' QOL by using questionnaires. However, our findings indicate favorable oncological outcomes, allowable toxicities and clinically meaningful prognostic factors of bladder-preserving therapy including PBT in a moderately large patient cohort with a strictly designed therapy regimen and followup protocol. In addition, our trimodal therapy may contribute to the improvement of patients' QOL, as we previously demonstrated that their bladder functions remain preserved after the treatment (27) .
In conclusion, our bladder-preserving therapy including PBT was well tolerated and achieved a favorable mortality rate. Patients with single and small (<5 cm) primary tumors are suitable for this therapy. Although any direct comparison between bladder-preserving therapy and RC is difficult because of the lack of large-scale randomized control studies, our results obtained from an over 20-year experience support the clinical benefit of PBT in MIBC, and we propose that this therapy can be a treatment option for selected patients with MIBC. 
